TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05112432

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cognitive and Social Cognitive Training
Description: The Cognitive Training Module is designed to improve the speed and accuracy of auditory information processing while engaging working memory and cognitive control under conditions of close attention and reward. Exercises continuously adjust difficulty level to user performance to maintain an approximately 80% current performance rate. The goal is to increase the effectiveness by which salient stimuli engage and drive plastic changes in brain systems that in individuals with psychosis exhibit relatively poor temporal response.~The Social Cognition Training Module consists of exercises designed to ameliorate core deficits in social cognition expressed in schizophrenia and Autism Spectrum Disorders. The exercises apply principles of implicit learning to restore the brain's capacity to process and utilize socially-relevant information, and include training to improve affect perception, social cue perception, theory of mind, self-referential style, and emotion labeling and working memory.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Real-Time Intervention for Motivational Enhancement (PRIME) App
Description: The PRIME smartphone-based app is designed to be used for 12 weeks to enhance motivation in people with early psychosis. Participants work towards self-identified goals with the support of the virtual community of age-matched peers, as well as with motivation coaches. Participants discuss their interests and aspirations with each other and with their coach, and the coach sends daily individualized motivational messages. Coaches also provide tailored interventions to enhance motivation, and post daily discussion topics to the PRIME community to encourage interaction between members. Coaches will maintain close communication and feedback on progress with each individual's clinical team.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Psychosis Coordinated Specialty Care
Description: Participants will continue to receive treatment as usual at their early psychosis coordinated specialty care clinics. These clinics may follow the NAVIGATE model, as an example.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early Psychosis Coordinated Specialty Care
Description: Participants will continue to receive treatment as usual at their early psychosis coordinated specialty care clinics. These clinics may follow the NAVIGATE model, as an example.
Study: NCT06561828

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham Theta Burst Stimulation (sham TBS)
Description: iTBS or cTBS delivered with placebo side of A/P coil.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham Theta Burst Stimulation (sham TBS)
Description: iTBS or cTBS delivered with placebo side of A/P coil.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham Theta Burst Stimulation (sham TBS)
Description: iTBS or cTBS delivered with placebo side of A/P coil.
Study: NCT04653129

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Fat Grafting
Description: * The fat grafts will be harvested from the abdomen or lateral thighs in a closed sterile system, then prepared according to Coleman guidelines. The blood and oil layers are then separated from the adipose tissue.~* The lipoaspirate will be injected based on a technique described by Vaienti et al, by 17-gaug cannula which will be inserted through the skin around the main incision at the nerve repair site, and the fat graft will be injected after closure of the skin.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Primary Nerve Repair
Description: Standard Epineural nerve repairs will be performed with 9/0 nylon sutures, under magnification by an operating microscope.
Study: NCT05514717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XMT-2056
Description: XMT-2056 will be administered through a vein in your arm or port catheter (intravenously)
Study: NCT06406465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat
Description: 400mg/m\^2/24h or 600 mg/m\^2/24h IV over (48h continuous infusion) on days 1, 2 and 3 based on UGT1A1 status

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat
Description: 400mg/m\^2/24h or 600 mg/m\^2/24h IV over (48h continuous infusion) on days 1, 2 and 3 based on UGT1A1 status

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 60 mg/m\^2 IV over 60 minutes on day 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 60 mg/m\^2 IV over 60 minutes on day 2
Study: NCT04653129

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary Nerve Repair
Description: Standard Epineural nerve repairs will be performed with 9/0 nylon sutures, under magnification by an operating microscope.
Study: NCT06406465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 80 mg/m\^2 IV over 60 minutes on day 2 after infusion of cisplatin and again on days 3 and 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 80 mg/m\^2 IV over 60 minutes on day 2 after infusion of cisplatin and again on days 3 and 4
Study: NCT05236660

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom-made shoes: pressure-optimized
Description: Pressure-optimized custom-made shoes: evaluated and optimized using in-shoe pressure analysis, and re-evaluated after 6 months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom-made indoor shoes: pressure optimized
Description: Pressure-optimized custom-made indoor shoes: evaluated and optimized using in-shoe pressure analysis, and re-evaluated after 6 months. Specifically designed for indoor use.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foot temperature monitoring
Description: Personalised at-home daily foot temperature monitoring at high-risk regions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Personalised patient education consisting of quantitative feedback on in-shoe pressures, temperature measurements and footwear use and, in addition, motivational interviewing where indicated and needed to improve device use.
Study: NCT06275919

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local Standard of Care
Description: In this setting there are not drugs with indication. Every site will treat patients as per their experience.
Study: NCT06414226

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Krill and Fish Oil vs. Placebo
Description: Participants were prescribed to take a daily dose of 4 capsules (4×500 mg= 2 g/day) stored at an appropriate temperature during the 8-week treatment period. The patients were informed to take 2 of the capsules in the bottle to be taken orally daily in the morning before breakfast and the other 2 capsules before dinner. The capsule bottles contained 500 mg concentrated krill oil, fish oil or placebo (empty capsule) capsules. The daily intake of EPA+DHA from krill and fish oil was determined as 520 mg and 600 mg, respectively. Krill and fish oil were obtained from Aniqnaturals Superba and Orzax Ocean company, respectively.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Krill and Fish Oil vs. Placebo
Description: Participants were prescribed to take a daily dose of 4 capsules (4×500 mg= 2 g/day) stored at an appropriate temperature during the 8-week treatment period. The patients were informed to take 2 of the capsules in the bottle to be taken orally daily in the morning before breakfast and the other 2 capsules before dinner. The capsule bottles contained 500 mg concentrated krill oil, fish oil or placebo (empty capsule) capsules. The daily intake of EPA+DHA from krill and fish oil was determined as 520 mg and 600 mg, respectively. Krill and fish oil were obtained from Aniqnaturals Superba and Orzax Ocean company, respectively.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Krill and Fish Oil vs. Placebo
Description: Participants were prescribed to take a daily dose of 4 capsules (4×500 mg= 2 g/day) stored at an appropriate temperature during the 8-week treatment period. The patients were informed to take 2 of the capsules in the bottle to be taken orally daily in the morning before breakfast and the other 2 capsules before dinner. The capsule bottles contained 500 mg concentrated krill oil, fish oil or placebo (empty capsule) capsules. The daily intake of EPA+DHA from krill and fish oil was determined as 520 mg and 600 mg, respectively. Krill and fish oil were obtained from Aniqnaturals Superba and Orzax Ocean company, respectively.
Study: NCT06524453

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wheelchair accessible exercise program
Description: 1. Stretching exercise~   * Dynamic and static~  * Neck, shoulder, elbow, wrist, trunk~  * 10 minutes~2. Aerobic exercise~   * High intensity interval training~  * Arm ergometer or wheelchair running~  * 20 mins~3. Strengthening exercise~   * Shoulder and chest, elbow joint major muscle; shoulder and trunk stabilization exercise~  * 3 sets of 10~  * 20 minutes~4. Stretching exercise~   * Dynamic and static~  * Neck, shoulder, elbow, wrist, trunk~  * 10 minutes
Study: NCT06459817

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BB-02 therapy
Description: Biophysical stimulation with magnetic fields

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BB-02 therapy
Description: Biophysical stimulation with magnetic fields
Study: NCT05373004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 MG
Description: It is the experimental drug in this trial. this drug has an approved efficacy in delaying kidney deterioration based on the results of (the EMPA-REG OUTCOME) trial. it is also recommended based on the ADA/EASD 2019 consensus, as the SGLT2 inhibitors are recommended in patients with type 2 diabetes in patients with CKD to prevent the progression of CKD. However, the previous trials where always add it to a patient already on an ACE inhibitor (in most cases). In this trial, it will be compared head to head with the gold standard treatment of CKD which is Enalapril 20 mg (ACE inhibitor).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril Maleate 20 mg
Description: It is an ACE inhibitor, the active comparator in this trial, and is considered the gold standard for the treatment of diabetic kidney disease.
Study: NCT04836897

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PrizValve® valve and transapical delivery system
Description: Transcatheter aortic valve replacement system
Study: NCT06779058

Intervention type: DEVICE
Intervention: MRE
Description: All imaging studies were performed by using a 1.5T/3.0-T MRI system

Intervention type: DEVICE
Intervention: MRE
Description: All imaging studies were performed by using a 1.5T/3.0-T MRI system

Intervention type: DEVICE
Intervention: Liver biopsy
Description: Liver biopsy are performed by well-trained pathologists in accordance with standard operating procedures.

Intervention type: DEVICE
Intervention: Liver biopsy
Description: Liver biopsy are performed by well-trained pathologists in accordance with standard operating procedures.
Study: NCT06777576

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hands-free exoskeleton
Description: A device trainer specialist from the investigation site will deliver training sessions with the exoskeleton to pair of participants (a pair corresponds to an individual with SCI and his/her companion). The device trainer will follow the progression of the pair through the training program and ensure they learn all the device basic skills. Each training session lasts an average of 1.5 hours, variations according to the user's learning pace and tolerance. During the sessions with the exoskeleton, the participants will engage in mobility activities on different surfaces and perform Activities of Daily Living in simulated environments such as kitchen, bathroom, elevators and outdoor spaces.
Study: NCT06777901

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auryon Atherectomy System
Description: Auryon Atherectomy System is composed of a laser and catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon Angioplasty
Description: Balloon Angioplasty alone
Study: NCT06778356

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Built environment
Description: Participants will complete the study session at a University student center.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Natural environment
Description: Participants will complete the study session in a nature trail.
Study: NCT06779097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vunakizumab (IL-17A inhibitor)
Description: Vunakizumab (IL-17A inhibitor)
Study: NCT06778460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine-lidocaine group
Description: In the esketamine-lidocaine group, patients received esketamine (0.25 mg/kg) and lidocaine (1.5 mg/kg) at the induction of anesthesia, followed by the continuous infusion of esketamine (0.02 mg/kg∙h) and lidocaine (1.5 mg/kg∙h) until the end of surgery. Postoperatively, the patients received two pumps. One pump delivered a fixed-rate infusion of lidocaine at 1.0 mg.kg-1.h-1 and esketamine at 0.02 mg.kg-1.h-1 infusion for 72 hours. Another PCIA device contained sufentanil 2 ug/kg, granisetron 12 mg diluted to 200 mL in 0.9 % normal saline.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: In the conventional analgesia group, patients received the same volume of normal saline instead of lidocaine and esketamine until the end of surgery. Postoperatively, the paitents received two pumps. One pump was the same volume of normal saline instead of lidocaine and esketamine. Another PCIA device contained sufentanil 2 ug/kg, granisetron 12 mg diluted to 200 mL in 0.9 % normal saline.
Study: NCT06079216

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Volunteer Led Making Connections Thru Music
Description: Volunteer led Group music therapy-based intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Staff Led Making Connections Thru Music
Description: Staff led Group music therapy-based intervention
Study: NCT05230550

Intervention type: DRUG
Intervention: Somapacitan
Description: Sogroya® therapy in participants with AGHD (only severe case) under normal clinical practice conditions
Study: NCT05873699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized 13-C-pyruvate
Description: Given by Injection
Study: NCT06148818

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive neck motor control exercise therapy
Description: The exercise programme will be conducted as a single session two days a week for 6 weeks. The sessions will always be conducted by the same physiotherapist. Each exercise session will consist of 10 minutes of warm-up exercises, 40 minutes of neck motor control exercises and 10 minutes of cool down exercises. Each exercise will be performed as 2 sets of 10 repetitions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive neck motor control exercise therapy
Description: The exercise programme will be conducted as a single session two days a week for 6 weeks. The sessions will always be conducted by the same physiotherapist. Each exercise session will consist of 10 minutes of warm-up exercises, 40 minutes of neck motor control exercises and 10 minutes of cool down exercises. Each exercise will be performed as 2 sets of 10 repetitions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive neck motor control exercise therapy
Description: The exercise programme will be conducted as a single session two days a week for 6 weeks. The sessions will always be conducted by the same physiotherapist. Each exercise session will consist of 10 minutes of warm-up exercises, 40 minutes of neck motor control exercises and 10 minutes of cool down exercises. Each exercise will be performed as 2 sets of 10 repetitions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient education
Description: The content of this education consists of information about the disease and symptoms, chewing recommendations, dietary changes, parafunctional habits, activities to be avoided, posture recommendations.

Intervention type: OTHER
Group type: OTHER
Intervention: Patient education
Description: The content of this education consists of information about the disease and symptoms, chewing recommendations, dietary changes, parafunctional habits, activities to be avoided, posture recommendations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient education
Description: The content of this education consists of information about the disease and symptoms, chewing recommendations, dietary changes, parafunctional habits, activities to be avoided, posture recommendations.
Study: NCT05610826

Intervention type: PROCEDURE
Group type: OTHER
Intervention: cytoreductive surgery
Description: Cytoreductive surgery is an operation to remove as much tumor tissue as possible.
Study: NCT06148818

Intervention type: OTHER
Group type: OTHER
Intervention: Patient education
Description: The content of this education consists of information about the disease and symptoms, chewing recommendations, dietary changes, parafunctional habits, activities to be avoided, posture recommendations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient education
Description: The content of this education consists of information about the disease and symptoms, chewing recommendations, dietary changes, parafunctional habits, activities to be avoided, posture recommendations.

Intervention type: OTHER
Group type: OTHER
Intervention: Patient education
Description: The content of this education consists of information about the disease and symptoms, chewing recommendations, dietary changes, parafunctional habits, activities to be avoided, posture recommendations.
Study: NCT05701085

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: The intervention will occur at a separate dedicated in-person visit with the patient navigator estimated to last 30-45 minutes. The Pre-Intervention Survey will be scored to generate a list of barriers identified for each patient. This list of barriers will be reviewed by the patient navigator prior to the intervention date. The patient will be asked to view educational videos on an iPad that correspond with each identified barrier. Afterwards, the patient navigator will lead a discussion based on the topics discussed.
Study: NCT05916170

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Warnings
Description: Text-only warnings about one health harm will be displayed in the hookah cafés where data collection is being conducted.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Warnings
Description: No warnings posted in the hookah café
Study: NCT05725161

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy (ACT)
Description: Participants assigned to the ACT group will receive 8 weekly individual ACT sessions guided by a coach for one hour per week over 8 weeks through Zoom videoconferencing with psychoeducation materials provided.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wait-list control group with psychoeducation materials provided
Description: The wait-list control group will receive care as usual with psychoeducation materials provided during the study period and receive ACT sessions after the study period ends
Study: NCT05653336

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PerQseal® Closure Device System
Description: Bioabsorbable implant delivered percutaneously to achieve haemostasis of common femoral arteriotomies created by 12 to 22 F sheaths (up to 26 F arteriotomy) in patients undergoing percutaneous catheter-based interventional procedures.
Study: NCT04733040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOR202
Description: MOR202 will be administered as an intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOR202
Description: MOR202 will be administered as an intravenous infusion
Study: NCT05150795

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 150mg
Description: Compare the postoperative analgesic effect of pre-operative oral pregabalin (Study group), to the intraoperative intravenous fentanyl (Control group) in diagnostic laparoscopic gynecologic surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl 100 micrograms ampoule
Description: Compare the postoperative analgesic effect of pre-operative oral pregabalin (Study group), to the intraoperative intravenous fentanyl (Control group) in diagnostic laparoscopic gynecologic surgery.
Study: NCT06293755

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microneedle patch
Description: with 20 units botulinum toxin
Study: NCT06382948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Patients will receive 7.5 mg of everolimus orally once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elacestrant
Description: Patients will receive elacestrant 345 mg orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elacestrant
Description: Patients will receive elacestrant 345 mg orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Patients will receive placebo orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Auxiliary Medicinal Product - Dexamethasone
Description: 10 mL of alcohol-free dexamethasone 0.5 mg per 5 mL mouthwashes (swish for 2 min and spit, four times daily for 8 weeks). After 8 weeks, dexamethasone mouthwash could be continued for up to eight additional weeks at the discretion of the clinician and patient. Used for prevention of treatment-induced stomatitis.
Study: NCT06293755

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intradermal injection
Description: with 20 units botulinum toxin
Study: NCT06382948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Auxiliary Medicinal Product - Dexamethasone
Description: 10 mL of alcohol-free dexamethasone 0.5 mg per 5 mL mouthwashes (swish for 2 min and spit, four times daily for 8 weeks). After 8 weeks, dexamethasone mouthwash could be continued for up to eight additional weeks at the discretion of the clinician and patient. Used for prevention of treatment-induced stomatitis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Auxiliary Medicinal Product - Luteinizing hormone-releasing hormone (LHRH) analogues
Description: According to clinical practice (for premenopausal/perimenopausal patients and male patients in both treatment arms). Used to suppress estrogen production.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Auxiliary Medicinal Product - Luteinizing hormone-releasing hormone (LHRH) analogues
Description: According to clinical practice (for premenopausal/perimenopausal patients and male patients in both treatment arms). Used to suppress estrogen production.